Due to maintenance work, this service will be unavailable Mon Feb 13 between
07:00 and
09:30 -
CET .
Apologies for the inconvenience.
UniProtKB/Swiss-Prot P29323 : Variant p.Met883Val
Ephrin type-B receptor 2
Gene: EPHB2
Variant information
Variant position: 883 The position of the amino-acid change on the UniProtKB canonical protein sequence.
Type of variant: LP/P [Disclaimer : Variants classification is intended for research purposes only, not for clinical and diagnostic use . The label disease variant is assigned according to literature reports on probable disease-association that can be based on theoretical reasons. This label must not be considered as a definitive proof for the pathogenic role of a variant. ]The variants are classified into three categories: LP/P, LB/B and US.LP/P: likely pathogenic or pathogenic. LB/B: likely benign or benign. US: uncertain significance
Residue change: From Methionine (M) to Valine (V) at position 883 (M883V, p.Met883Val).Indicates the amino acid change of the variant. The one-letter and three-letter codes for amino acids used in UniProtKB/Swiss-Prot are those adopted by the commission on Biochemical Nomenclature of the IUPAC-IUB.
Physico-chemical properties: Similar physico-chemical property. Both residues are medium size and hydrophobic.The physico-chemical property of the reference and variant residues and the change implicated.
BLOSUM score: 1The score within a Blosum matrix for the corresponding wild-type to variant amino acid change. The log-odds score measures the logarithm for the ratio of the likelihood of two amino acids appearing by chance. The Blosum62 substitution matrix is used. This substitution matrix contains scores for all possible exchanges of one amino acid with another: Lowest score: -4 (low probability of substitution).Highest score: 11 (high probability of substitution). More information can be found on the following page
Variant description: In prostate cancer.Any additional useful information about the variant.
Other resources: Links to websites of interest for the variant.
Sequence information
Variant position: 883 The position of the amino-acid change on the UniProtKB canonical protein sequence.
Protein sequence length: 1055 The length of the canonical sequence.
Location on the sequence:
WQKDRNHRPKFGQIVNTLDK
M IRNPNSLKAMAPLSSGINLP
The residue change on the sequence. Unless the variant is located at the beginning or at the end of the protein sequence, both residues upstream (20) and downstream (20) of the variant will be shown.
Residue conservation: The multiple alignment of the region surrounding the variant against various orthologous sequences.
Human WQKDRNHRPKFGQIVNTLDKM IRNPNSLKAMAPLSSGINLP
Mouse WQKDRNHRPKFGQIVNTLDKM IRNPNSLKAMAPLSSGINLP
Chicken WQKDRNHRPKFGQIVNTLDKM IRNPNSLKAMAPLSSGVNLP
Sequence annotation in neighborhood: The regions or sites of interest surrounding the variant. In general the features listed are posttranslational modifications, binding sites, enzyme active sites, local secondary structure or other characteristics reported in the cited references. The "Sequence annotation in neighborhood" lines have a fixed format:Type: the type of sequence feature. Positions: endpoints of the sequence feature. Description: contains additional information about the feature.
Type Positions Description
Chain
19 – 1055
Ephrin type-B receptor 2
Chain
536 – 986
EphB2/CTF1
Chain
562 – 986
EphB2/CTF2
Topological domain
565 – 1055
Cytoplasmic
Domain
621 – 884
Protein kinase
Cross
891 – 891
Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in ubiquitin)
Mutagenesis
891 – 891
K -> R. Complete loss of ubiquitination by RNF186.
Helix
873 – 885
Literature citations
A common nonsense mutation in EphB2 is associated with prostate cancer risk in African American men with a positive family history.
Kittles R.A.; Baffoe-Bonnie A.B.; Moses T.Y.; Robbins C.M.; Ahaghotu C.; Huusko P.; Pettaway C.; Vijayakumar S.; Bennett J.; Hoke G.; Mason T.; Weinrich S.; Trent J.M.; Collins F.S.; Mousses S.; Bailey-Wilson J.; Furbert-Harris P.; Dunston G.; Powell I.J.; Carpten J.D.;
J. Med. Genet. 43:507-511(2006)
Cited for: VARIANTS PROSTATE CANCER SER-279; ALA-650 AND VAL-883;
Disclaimer:
Any medical or genetic information present in this entry is provided for research, educational and informational purposes only. They are not in any way intended to be used as a substitute for professional medical advice, diagnostic, treatment or care.